Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Rogely Boyce"'
3
Akademický článek
Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs
Autor: Neil Bodick, Toni Williamson, Vibeke Strand, Becca Senter, Scott Kelley, Rogely Boyce, Ruth Lightfoot-Dunn
Publikováno v: Rheumatology and Therapy, Vol 5, Iss 2, Pp 475-498 (2018)
Abstract Introduction Single intra-articular (IA) injections of poly(lactic-co-glycolic acid) (PLGA) microsphere-based triamcinolone acetonide extended-release (TA–ER; formerly FX006) demonstrated sustained, clinically relevant benefits in patients
Externí odkaz: https://doaj.org/article/978adfc99c6e4324aa1882602b9e826a
Zobrazit plný text záznamu
4
Efficacy and Safety of FX201, a Novel Intra-Articular IL-1Ra Gene Therapy for Osteoarthritis Treatment, in a Rat Model
Autor: Rebecca Senter, Rogely Boyce, Marko Repic, Emily Walsh Martin, Monika Chabicovsky, Geneviève Langevin-Carpentier, Agathe Bédard, Neil Bodick
Publikováno v: Human gene therapy. 33(9-10)
Osteoarthritis (OA) is a disabling, degenerative disease characterized by progressive cartilage and bone damage. There remains a need for local therapies that, following a single injection, can provide long-term pain relief and functional improvement
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fba8de7107cd8a2bdc2f91d14a2829b
https://pubmed.ncbi.nlm.nih.gov/34963343
Zobrazit plný text záznamu
5
854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models
Autor: Esther S. Trueblood, Natalya Nazarenko, Sasha Lucas, Angela Epp, John Gosink, Michelle Ulrich, Alyson Smith, Sean Allred, Piper M. Treuting, Chris Frantz, Jason Schrum, Julie Hahn, Elizabeth E. Gray, Jane Haass, Shyra Gardai, Rogely Boyce, Kelly Hensley, Katie Snead, Disha Sahetya
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundSGN-B7H4V is a novel, investigational vedotin antibody drug conjugate (ADC) directed to B7-H4, a member of the B7 family of immune checkpoint ligands. B7-H4 expression is elevated on a variety of solid tumors including breast, ovarian, and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38201f1e03172eebe8ef83fa795048da
https://doaj.org/article/69edefe076c94b3782fb3ef57afa2c8f
Zobrazit plný text záznamu
6
Bone Therapeutics: Safety Considerations, Session Summary
Autor: Christopher P. Jerome, Rogely Boyce
Publikováno v: Toxicologic Pathology. 45:855-858
This session was a series of presentations focused on safety considerations for late stage or currently marketed bone therapeutic agents. The first presentation was an overview of a major regulatory requirement in the nonclinical filing package for b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::204502e1991b04a289ead473ed50b169
https://doi.org/10.1177/0192623317737231
Zobrazit plný text záznamu
7
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists
Autor: Xiaodong, Li, Shanaka, Stanislaus, Frank, Asuncion, Qing-Tian, Niu, Narumol, Chinookoswong, Kelly, Villasenor, Jin, Wang, Philip, Wong, Rogely, Boyce, Denise, Dwyer, Chun-Ya, Han, Michelle M, Chen, Benxian, Liu, Marina, Stolina, Hua Zhu, Ke, Michael S, Ominsky, Murielle M, Véniant, Jing, Xu
Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 32(4)
Results of prior studies suggest that fibroblast growth factor 21 (FGF21) may be involved in bone turnover and in the actions of peroxisome proliferator-activated receptor (PPAR) α and γ in mice. We have conducted independent studies to examine the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::60eb2df1cdd65dda9b0a20074f1b166f
https://pubmed.ncbi.nlm.nih.gov/27505721
Zobrazit plný text záznamu
9
Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity
Autor: Marcia Renzetti, Jones Philip Stephen, Ralph Garippa, Glyn Williams, Joseph A. Sergi, Ying Peng, Kevin Richard Guertin, Fiorenza Falcioni, Hilary A. Overton, Lida Qi, Rogely Boyce, Andrée R. Olivier, Karen Wang, Rachel M. Dunsdon, Mathew Taylor, Brian William Dymock, Lina Setti
Publikováno v: Bioorganic & Medicinal Chemistry Letters. 13:2895-2898
A novel series of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents have been identified. These compounds show non-selective inhibitory properties against a panel of protein tyrosine phosphatases including PTP1B. Comp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a17384433d52272fadaa8c14dd8bbe1
https://doi.org/10.1016/s0960-894x(03)00623-1
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje